More Evidence Evolocumab Exceeds Cost-Effectiveness

Share this content:
More Evidence Evolocumab Exceeds Cost-Effectiveness
More Evidence Evolocumab Exceeds Cost-Effectiveness

FRIDAY, Aug. 25, 2017 (HealthDay News) -- At its current price, the addition of evolocumab to standard therapy in patients with atherosclerotic cardiovascular disease generally exceeds accepted cost-effectiveness thresholds, according to a study published online Aug. 23 in JAMA Cardiology.

Gregg C. Fonarow, M.D., from the Ronald Reagan University of California in Los Angeles, and colleagues examined the cost-effectiveness of evolocumab in patients with atherosclerotic cardiovascular disease. A Markov cohort state-transition model was used, which included U.S. population-specific demographics, risk factors, background therapy, and event rates, as well as trial-based event risk reduction.

The researchers found that evolocumab was associated with increased cost and improved quality-adjusted life-year (QALY) in the base case, using U.S. clinical practice patients with atherosclerotic cardiovascular disease with low-density lipoprotein cholesterol levels of ≥70 mg/dL and an annual events rate of 6.4 per 100 patient-years: incremental cost $105,398; incremental QALY, 0.39, with an incremental cost effectiveness ratio (ICER) of $268,637 per QALY gained. ICERs varied from $100,193 to $488,642 per QALY in sensitivity and scenario analyses, with ICER of $413,579 per QALY for trial patient characteristics and event rate of 4.2 per 100 patient-years. In most scenarios, evolocumab treatment exceeded $150,000 per QALY.

"To achieve an ICER of $150,000 per QALY, the annual net price would need to be substantially lower ($9,669 for U.S. clinical practice and $6,780 for trial participants), or a higher-risk population would need to be treated," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Amgen, which manufactures evolocumab and funded the study.

Abstract/Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC Launches Campaign to Fight Prescription Opioid Epidemic

CDC Launches Campaign to Fight Prescription Opioid Epidemic

Rx Awareness campaign uses testimonials to educate the public, increase awareness about risks

Liraglutide Linked to Reduction in VAT, Improvement in -Index

Liraglutide Linked to Reduction in VAT, Improvement in ...

Significant improvement in IGF-II serum levels with liraglutide for obese with prediabetes, early T2DM

Nut Consumption Linked to Nutritionally Rich Food Intake

Nut Consumption Linked to Nutritionally Rich Food Intake

Nut consumers eat more fruits, vegetables, less red meat, and have lower BMI than non-nut consumers

is free, fast, and customized just for you!

Already a member?

Sign In Now »